Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – January 16, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – January 15, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – January 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 13, 2025 | Press Releases

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell CarcinomaMarlborough, Massachusetts–(Newsfile Corp. – January 13, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing...

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Jan 2, 2025 | Press Releases

INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentationMarlborough, Massachusetts–(Newsfile Corp. – January 2, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing...